Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma
Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma
Background:
Few studies have investigated the use of specific immunotherapy (SIT) for childhood seasonal allergic asthma.
Objective:
We sought to examine the efficacy and safety of SIT with Alutard SQ grass pollen (Phleum pratense Alutard SQ; ALK-Abelló, Hørsholm, Denmark) in children with seasonal allergic asthma.
Methods:
A randomized, double-blind, placebo-controlled study assessing the efficacy of grass pollen SIT over 2 pollen seasons was performed. Children (3-16 years) with a history of seasonal allergic asthma sensitized to grass pollen (P pratense) and requiring at least 200 ?g of inhaled beclomethasone equivalent per day were enrolled. Subjects with symptomatic asthma or rhinoconjunctivitis outside the grass pollen season were excluded. The primary outcome measure was a combined asthma symptom-medication score during the second pollen season. Secondary outcome measures included end-point titration skin prick testing and conjunctival and bronchial provocation testing to allergen, sputum eosinophilia, exhaled nitric oxide, and adverse events.
Results:
Thirty-nine subjects were enrolled. Thirty-five subjects provided data for analysis. The use of SIT was associated with a substantial reduction in asthma symptom-medication score compared with that after placebo (P = .04). There were also significant reductions in cutaneous (P = .002), conjunctival (P = .02), and bronchial (P = .01) reactivity to allergen after SIT compared with that after placebo. The 2 groups had similar levels of airway inflammation, despite a trend toward less inhaled steroid use in the active group. No serious adverse events were reported, and no subjects withdrew because of adverse events.
Conclusion:
The study has shown that SIT is effective and well tolerated in children with seasonal allergic asthma to grass pollen.
seasonal allergic asthma, children, immunotherapy
263-268
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Hurley, Catriona
7ed3fff1-7a17-4763-a70f-4b7180b2bc7d
Turcanu, Victor
8cfa4bfb-3ef3-484d-8211-3572a1754185
Lack, Gideon
cac030a2-c358-4880-a91d-d67d06e8e321
February 2006
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Hurley, Catriona
7ed3fff1-7a17-4763-a70f-4b7180b2bc7d
Turcanu, Victor
8cfa4bfb-3ef3-484d-8211-3572a1754185
Lack, Gideon
cac030a2-c358-4880-a91d-d67d06e8e321
Roberts, Graham, Hurley, Catriona, Turcanu, Victor and Lack, Gideon
(2006)
Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Journal of Allergy and Clinical Immunology, 117 (2), .
(doi:10.1016/j.jaci.2005.09.054).
Abstract
Background:
Few studies have investigated the use of specific immunotherapy (SIT) for childhood seasonal allergic asthma.
Objective:
We sought to examine the efficacy and safety of SIT with Alutard SQ grass pollen (Phleum pratense Alutard SQ; ALK-Abelló, Hørsholm, Denmark) in children with seasonal allergic asthma.
Methods:
A randomized, double-blind, placebo-controlled study assessing the efficacy of grass pollen SIT over 2 pollen seasons was performed. Children (3-16 years) with a history of seasonal allergic asthma sensitized to grass pollen (P pratense) and requiring at least 200 ?g of inhaled beclomethasone equivalent per day were enrolled. Subjects with symptomatic asthma or rhinoconjunctivitis outside the grass pollen season were excluded. The primary outcome measure was a combined asthma symptom-medication score during the second pollen season. Secondary outcome measures included end-point titration skin prick testing and conjunctival and bronchial provocation testing to allergen, sputum eosinophilia, exhaled nitric oxide, and adverse events.
Results:
Thirty-nine subjects were enrolled. Thirty-five subjects provided data for analysis. The use of SIT was associated with a substantial reduction in asthma symptom-medication score compared with that after placebo (P = .04). There were also significant reductions in cutaneous (P = .002), conjunctival (P = .02), and bronchial (P = .01) reactivity to allergen after SIT compared with that after placebo. The 2 groups had similar levels of airway inflammation, despite a trend toward less inhaled steroid use in the active group. No serious adverse events were reported, and no subjects withdrew because of adverse events.
Conclusion:
The study has shown that SIT is effective and well tolerated in children with seasonal allergic asthma to grass pollen.
This record has no associated files available for download.
More information
Published date: February 2006
Keywords:
seasonal allergic asthma, children, immunotherapy
Identifiers
Local EPrints ID: 40650
URI: http://eprints.soton.ac.uk/id/eprint/40650
ISSN: 0091-6749
PURE UUID: f388aaf1-02d2-482c-b953-d596472304ff
Catalogue record
Date deposited: 06 Jul 2006
Last modified: 16 Mar 2024 03:44
Export record
Altmetrics
Contributors
Author:
Catriona Hurley
Author:
Victor Turcanu
Author:
Gideon Lack
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics